Genmab out-licenses HuMax-IL8 to Cormorant

Genmab A/S (CSE:GEN) granted Cormorant Pharmaceuticals AB (Stockholm, Sweden) exclusive, worldwide rights to HuMax-IL8, a human IgG1,kappa antibody targeting IL-8 that has completed a Phase I/II trial...